drugset / Trial / NCT02253862

Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

NCT02253862

Phase 1 Completed 17 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to assess the effects of single-dose and steady-state tipranavir/ritonavir 500 mg/200 mg on the single-dose pharmacokinetics of tadalafil 10 mg

Timeline

Start
2005-12
Primary completion
2006-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 200 mg
Subject Tadalafil Small molecule 10 mg Oral
Subject Tipranavir Small molecule 500 mg

Indications

No indication recorded.